DS
LXEO icon

David Shaw’s Lexeo Therapeutics LXEO Stock Holding History

David Shaw’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.5K Sell
19,866
-10,611
-35% -$57.4K ﹤0.01% 4652
2026
Q1 		$175K Sell
30,477
-449,728
-94% -$3.19M ﹤0.01% 4225
2025
Q4 		$4.77M Buy
480,205
+467,387
+3,646% +$4.26M ﹤0.01% 2347
2025
Q3 		$85.1K Buy
+12,818
New +$62K ﹤0.01% 4368

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

David Shaw's LXEO Position: Q2 2026 in Review

David Shaw reduced its Lexeo Therapeutics (LXEO) stake by 35% in Q2 2026, selling an estimated $57.4K and leaving 19,866 shares worth $92.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4652.

David Shaw first reported a position in LXEO in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.77M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • David Shaw held 19,866 shares of Lexeo Therapeutics worth $92.5K as of Q2 2026.
  • David Shaw sold 10,611 Lexeo Therapeutics shares in Q2 2026, an estimated $57.4K.
  • Lexeo Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4652 holding.
  • David Shaw first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • David Shaw's Lexeo Therapeutics position peaked at $4.77M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.